Profile picture of Dr. John L. Hopper

Oncologist

Australian Flag

John L. Hopper

Icon representing available degree

MSc, PhD

Icon that representing available experience

51 Years Overall Experience

Icon representing available city of this doctor

Carlton

Quick Appointment for John L. Hopper

No OPD information available

Services Offered by John L. Hopper

  • Breast Cancer

  • Colorectal Cancer

  • Familial Colorectal Cancer

  • Lynch Syndrome

  • Endometrial Cancer

  • Familial Prostate Cancer

  • Menopause

  • Oophorectomy

  • Ovarian Cancer

  • Restless Legs Syndrome

  • Ring Chromosome 12

  • Salpingo-Oophorectomy

  • Turcot Syndrome

  • Anal Cancer

  • Asthma

  • BRCA Positive Breast Cancer

  • Hemochromatosis

  • Prostate Cancer

  • Ring Chromosome 6

  • Age-Related Macular Degeneration (ARMD)

  • Allergic Rhinitis

  • Atopic Dermatitis

  • Autosomal Recessive Hypotrichosis

  • B-Cell Lymphoma

  • Brain Tumor

  • Breast Cancer in Men

  • Bronchitis

  • Cervical Dysplasia

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Chronic Pain

  • Colonoscopy

  • Congenital Aplastic Anemia

  • Endoscopy

  • Familial Adenomatous Polyposis

  • Fanconi Anemia

  • Fragile X Syndrome

  • Genetic Epilepsy with Febrile Seizures Plus (GEFS+)

  • Headache

  • Hormone Replacement Therapy (HRT)

  • Hysterectomy

  • Late-Onset Retinal Degeneration

  • Li-Fraumeni Syndrome

  • Liver Spots

  • Lung Cancer

  • Mastectomy

  • Measles

  • Melanoma

  • Melasma

  • Migraine

  • Non-Hodgkin Lymphoma

  • Obesity

  • Obsessive-Compulsive Disorder (OCD)

  • Osteoarthritis

  • Osteoporosis

  • Pancreatic Cancer

  • Parainfluenza

  • Precocious Puberty

  • Premature Ovarian Failure

  • Renal Cell Carcinoma (RCC)

  • Stridor

  • Sunburn

  • Type 2 Diabetes (T2D)

  • Urothelial Cancer

About Of John L. Hopper

John L. Hopper is a male medical professional who helps people with various health issues like cancer, asthma, and diabetes. He is skilled in treating conditions like breast cancer, prostate cancer, and migraines. He also helps with procedures like colonoscopies and hysterectomies.

John L. Hopper talks to patients in a way they can understand, making them feel comfortable and cared for. Patients trust him because he listens to their concerns and explains things clearly. He uses his knowledge and experience to provide the best care possible.

To stay updated with the latest medical information, John L. Hopper reads research papers and attends conferences. This helps him learn about new treatments and technologies so he can offer the most effective care to his patients.

John L. Hopper works well with other medical professionals, collaborating to ensure patients receive comprehensive care. He values teamwork and respects his colleagues' expertise, creating a supportive environment for everyone involved.

Through his work, John L. Hopper has positively impacted many patients' lives. His dedication to improving health outcomes and providing compassionate care has made a difference in the community. His research on gender diversity in twin studies has contributed valuable insights to the medical field.

Overall, John L. Hopper is a dedicated and knowledgeable healthcare provider who puts his patients' well-being first. His commitment to staying informed, working collaboratively, and making a difference in people's lives sets him apart as a trusted and respected medical professional.

Education of John L. Hopper

  • MSc - Monash University, 1974

  • PhD - La Trobe University,1980

Memberships of John L. Hopper

  • National Health and Medical Research Council Australia Fellowship (2007)

Publications by John L. Hopper

Capturing Gender Diversity in Twin Research.

Journal: Twin research and human genetics : the official journal of the International Society for Twin Studies
Year: April 15, 2025
Authors: Will Conabere, Anja Ravine, Louise Bourchier, Sue Malta, Jessica Tyler, Shuai Li, John Hopper, Ken Pang

Description:Most twin registries have not systematically collected the data required to determine gender identity, which has limited opportunities to evaluate potential familial contributors to gender diversity. This study addresses this gap by analyzing responses to gender identity questions introduced in Twins Research Australia's 2023 survey. Among 4475 respondents (mean age 52.2 years, SD = 15.3), 36 (0.8%) indicated a transgender or gender diverse identity, which is consistent with population-based estimates of gender diversity internationally. Gender diversity co-occurred in 2/19 monozygotic pairs and 0/8 dizygotic pairs, giving rise to tetrachoric correlations of 0.62 (95% CI [0.33, 0.87]) and 0.00 (95% CI [0.00, 0.88]), respectively. These results broadly align with previous concordance estimates from twin studies that were specifically focused on gender identity. Although limited by a small sample size, these findings demonstrate the feasibility and utility of systematically collecting gender identity data through routine twin registry surveys.

Adverse late outcomes in long-term survivors of young adult Hodgkin lymphoma (YAHL) compared to their unaffected co-twins.

Journal: Leukemia & lymphoma
Year: May 01, 2025
Authors: Marcie Haydon, Amie Hwang, Niquelle Wadé, Jun Wang, Jia Wan, Marta Epeldegui, Yu Guo, Laura Buchanan, Esther Lam, Larry Magpantay, Shuai Li, Lucas Calais Ferreira, Joel Milam, Otoniel Martinez Maza, Thomas Mack, John Hopper, David Conti, Wendy Cozen

Description:Late-onset conditions have been reported in young adult Hodgkin lymphoma (YAHL) survivors but the use of convenience controls may bias estimates. Thirty-five YAHL survivors and their unaffected co-twins completed an online questionnaire on such conditions. McNemar's test and conditional logistic and random-effects linear regression were used to assess differences. On average, YAHL survivors (54.3% monozygotic, 57.1% female) were 27.1 years at diagnosis and 29.7 years post-diagnosis at participation. Survivors had increased risk of secondary malignancy (OR = 4.33), cardiac (12 cases/0 co-twins), lung (6 cases/0 co-twins), and thyroid conditions (18 cases/0 co-twins), and increased utilization of cardiac (OR = 9.00) and thyroid tests (OR = 10.00) compared to their co-twin. Non-significant trends in life milestone achievement, including greater college degree attainment, earlier retirement, and fewer biological children, were also observed in YAHL survivors. Life satisfaction was significantly lower among YAHL survivors (p = .035). Decades after diagnosis, differences in late outcomes were observed in YAHL survivors compared to co-twin controls, providing a more accurate assessment of the late effects of YAHL.

Opposing effects between retinoic acid and Fibroblast growth factor in patterning the common crus and semicircular canals of the inner ear.

Journal: Developmental biology
Year: February 25, 2025
Authors: Weise Chang, John Hopper, Doris Wu

Description:The three orthogonally arranged semicircular canals and their sensory organs, cristae, of the inner ear are responsible for detecting angular head movements. A main functional component of this vestibular apparatus is the evolutionarily conserved unit of the anterior and posterior canals joined by a central stalk, the common crus. A resorption process (removal of epithelial cells) carves out these three connecting structures from an epithelial outpocket of the developing otic vesicle known as the vertical canal pouch. While molecules such as Fibroblast growth factors (FGF) and Bone morphogenetic proteins (BMP) emanating from the prospective sensory cristae and the rim of the canal pouch, counteract with the resorption process to form the canals, it is not known if there is an independent mechanism that mediates common crus formation. Here, we show that genes encoding retinoic acid (RA) synthesizing enzymes, Aldh1a2 and Aldh1a3, are expressed in the presumptive common crus region of the canal pouch. Blocking endogenous RA activity abolishes common crus formation. Endogenous RA may mediate common crus formation by limiting proliferation of the peri-otic mesenchyme at the prospective common crus region and thus counteracting the resorption process. Additionally, RA and FGF antagonize each other in patterning the common crus and canals, respectively. Ectopic FGF2 downregulates Aldh1a2 expression in the common crus, whereas Bmp2, required for canal formation, may be an intermediate which is co-regulated by RA and FGF.

Allergic disease and risk of multiple myeloma: A case-control study.

Journal: Cancer epidemiology
Year: December 22, 2024
Authors: Simon Cheah, Adrian Lowe, Nina Afshar, Julie Bassett, Fiona Bruinsma, Wendy Cozen, Simon Harrison, John Hopper, Harindra Jayasekara, H Prince, Claire Vajdic, Nicole Doo, Graham Giles, Shyamali Dharmage, Roger Milne

Description:Objective: Multiple myeloma (MM) is responsible for significant morbidity and mortality, yet our knowledge regarding MM aetiology remains limited. We investigated whether a history of allergic conditions is associated with MM risk. Methods: Incident cases (n = 782) of MM were recruited via cancer registries in Victoria and NSW. Controls (n = 733) were siblings (n = 436) or spouses (n = 297) of cases. Unconditional logistic regression was used to estimate odds ratios (OR) and 95 % confidence intervals (CI) for associations between self-reported allergic conditions (asthma, eczema, food allergy, hay fever) and MM risk. Results: Eczema was inversely associated with MM risk (OR = 0.54, 95 %CI = 0.42-0.70), as was a combined history of food allergy and eczema (OR = 0.52, 95 %CI = 0.29-0.93). There was an inverse association between a history of any allergic condition (compared with none) and risk of MM (OR = 0.68, 95 %CI = 0.55-0.84). In the mean-centred dose-risk analysis the OR was 0.87 (95 %CI = 0.73-1.04) per additional allergic condition of interest. No notable associations were identified for food allergy, asthma, or hay fever alone. Conclusions: We found that a history of allergic disease, particularly eczema, was associated with reduced MM risk. Further research is recommended to confirm findings and investigate potential mechanisms.

Cancer incidence inconsistency between UK Biobank participants and the population: a prospective cohort study.

Journal: BMC Medicine
Year: December 09, 2024
Authors: Chenxi Li, Gillian Dite, Tuong Nguyen, John Hopper, Shuai Li

Description:Background: While the UK Biobank has been widely used for cancer research, its representativeness of the population in terms of cancer incidence has not been thoroughly investigated. Methods: We conducted a prospective cohort study of 466,163 UK Biobank participants who were cancer-free at recruitment. Standardised incidence ratios (SIRs) were calculated for all cancers combined and for 25 cancers, by comparing incidences for the participants with the UK national incidences. Variations in SIR by age, sex and deprivation measures were investigated. Results: Over a median follow-up period of 12 years, 47,535 participants had a cancer diagnosis. The SIR for all cancers combined was 0.90 (95% CI: 0.89, 0.91). The SIR increased with age and deprivation (P = 10-9). The SIRs of 17 cancers differed from 1 (Bonferroni-adjusted P < 0.05): for prostate cancer and melanoma the SIRs were 1.2 and for the other 15 cancers the SIRs ranged from 0.43 to 0.93. The SIRs of 13 cancers differed by deprivation: the greater the deprivation, the lower the SIRs for prostate cancer and melanoma, and the higher the SIRs for the other 11 cancers. Conclusions: The overall cancer incidence was 10% lower for the UK Biobank participants compared with the population, with most cancers having a lower incidence that increased with deprivation. Irrespective of their causes, the inconsistencies could bias UK Biobank research results related to absolute cancer risks, such as the development and/or validation of cancer risk models and penetrance estimates for cancer susceptibility genes.

Frequently Asked Questions About John L. Hopper

What conditions does John L. Hopper specialize in treating as an oncologist?

John L. Hopper specializes in diagnosing and treating various types of cancer, including but not limited to breast cancer, lung cancer, colon cancer, and prostate cancer.

What services does John L. Hopper offer as an oncologist?

John L. Hopper offers a range of services such as cancer screenings, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and palliative care to help manage cancer symptoms and improve quality of life.

How does John L. Hopper approach personalized treatment plans for cancer patients?

John L. Hopper takes a personalized approach by considering each patient's unique medical history, type and stage of cancer, genetic factors, and treatment preferences to develop tailored treatment plans that best suit their individual needs.

What are some common side effects of cancer treatments that patients may experience?

Common side effects of cancer treatments such as chemotherapy and radiation therapy may include fatigue, nausea, hair loss, changes in appetite, and increased risk of infections. John L. Hopper works closely with patients to manage these side effects and improve their overall well-being during treatment.

How does John L. Hopper support patients and their families throughout the cancer journey?

John L. Hopper provides compassionate care and emotional support to patients and their families by offering counseling, resources for coping with the emotional impact of cancer, and guidance on navigating the healthcare system to ensure comprehensive care.

What should patients expect during their initial consultation with John L. Hopper?

During the initial consultation, John L. Hopper will review the patient's medical history, perform a physical examination, discuss diagnostic tests and treatment options, and address any questions or concerns the patient may have about their cancer diagnosis and treatment plan.

More Oncologist Like John L. Hopper in Carlton

Toparrow